The stock of Oncolytics Biotech, Inc (ONCY) has gone up by 20.11% for the week, with a -4.53% drop in the past month and a -31.60% drop in the past quarter. The volatility ratio for the week is 11.14%, and the volatility levels for the past 30 days are 6.28% for ONCY.. The simple moving average for the past 20 days is 3.90% for ONCY’s stock, with a -34.30% simple moving average for the past 200 days.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ONCY is 84.87M, and currently, short sellers hold a 3.54% ratio of that floaft. The average trading volume of ONCY on April 11, 2025 was 1.05M shares.
ONCY) stock’s latest price update
Oncolytics Biotech, Inc (NASDAQ: ONCY) has experienced a rise in its stock price by 18.94 compared to its previous closing price of 0.50. However, the company has seen a gain of 20.11% in its stock price over the last five trading days. prnewswire.com reported 2025-04-10 that SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at -9.26% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.12% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 11.14%, as shares sank -2.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.76% lower at present.
During the last 5 trading sessions, ONCY rose by +23.04%, which changed the moving average for the period of 200-days by -39.67% in comparison to the 20-day moving average, which settled at $0.5732. In addition, Oncolytics Biotech, Inc saw -34.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -1.97. Equity return is now at value -184.69, with -106.47 for asset returns.
Based on Oncolytics Biotech, Inc (ONCY), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -18.94.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.82.
Conclusion
In a nutshell, Oncolytics Biotech, Inc (ONCY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
